Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OSI-774 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| OSI-774 & bevacizumab | EXPERIMENTAL | OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days. |
| Name | Type | Description |
|---|---|---|
| OSI-774 | DRUG | 150mg PO, days 1-28, cycle repeated every 28 days |
| Bevacizumab | DRUG | 10mg/kg, IV infusion, Days 1 and 15, 28 day cycles |
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Metastatic or unresectable clear cell kidney cancer confirmed by biopsy * Previous nephrectomy * Maximum of 1 previous regimen for metastatic disease * Ability to perform activities of daily living with minim...
Top 20 of 36 competitors
OSI-774 is an investigational small molecule being studied for the treatment of kidney cancer, specifically metastatic renal cell carcinoma. It is in Phase 2 clinical development and has been evaluated in a completed clinical trial in the United States.
OSI-774 is a small molecule that targets the epidermal growth factor receptor (EGFR). It is being investigated as a potential treatment for kidney cancer, specifically metastatic renal cell carcinoma, and is currently in Phase 2 clinical development.
OSI-774 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 2 clinical development for the treatment of kidney cancer.
OSI-774 is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of kidney cancer, specifically metastatic renal cell carcinoma. It has completed a Phase 2 clinical trial and is not yet approved by regulatory authorities.
OSI-774 has been studied in a completed Phase 2 clinical trial with the identifier NCT00193154. This trial evaluated OSI-774 in combination with bevacizumab in patients with metastatic renal cell carcinoma and enrolled 63 participants in the United States.
OSI-774 is also known as erlotinib, a small molecule that targets the epidermal growth factor receptor (EGFR). It is being developed by AstraZeneca PLC and is currently in Phase 2 clinical development for the treatment of kidney cancer.